Role of PI3K-AKT-mTOR signaling pathway-related circular RNAs in the diagnosis and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis

Author:

Wang Shuaiyang1,Wu Mei2,Xie Bei3,Tian Ye1,Ma Xingyuan1,Li Jing1,Ma Bin2,Li Linjing1

Affiliation:

1. Lanzhou University Second Hospital

2. Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University

3. Department of Immunology, School of Basic Medical Sciences, Lanzhou University

Abstract

Abstract

Background Several studies have demonstrated that phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)-related circular RNAs (circRNAs) play a role in the development and progression of hepatocellular carcinoma (HCC). However, a systematic review and meta-analysis of the role of PI3K/AKT-related circRNAs in the diagnosis and prognosis of HCC has not been reported at present. Herein, we systematically reviewed the literature and conducted a meta-analysis of the potential role of PI3K/AKT/mTOR-related circRNAs in the diagnosis and prognosis of HCC. Method PubMed, EMBASE, Cochrane Library, Web of Science, Scoups, Wanfang, Chinese Biomedical Literature Database (SinoMed), Chinese National Knowledge Infrastructure (CNKI) and Chinese Science and Technique Journals Database (VIP) databases were searched for relevant studies from inception to April 19, 2024. Pooled odds ratio (OR) was used to evaluate clinical case characteristics, sensitivity and specificity. Prognostic overall survival (OS) was estimated using the hazard ratio (HR). Subgroup analyses were conducted according to sample type, country and control group type. The quality of each study was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool or the Newcastle-Ottawa Scale (NOS) method, and Egger’s tests were used to assess potential publication bias. STATA (version 17.0) software was used for statistical analysis. Results Twenty five eligible articles, including ten diagnostic studies and sixteen prognostic studies, involving 2995 HCC patients, 435 healthy controls and 338 controls with benign lesions were included in this meta-analysis. The pooled sensitivity and specificity were 0.80 (95% CI: 0.75–0.84) and 0.86 (95% CI: 0.77–0.92), respectively. Higher levels of PI3K/AKT/mTOR pathway-associated circRNAs are significantly associated with poor patient prognosis (OS:HR = 1.49, 95% Cl: 0.89–2.48, P < 0.001). Elevated levels of highly expressed circRNAs in patients were significantly associated with HbsAg positivity, MVI positivity, and worse TMN staging in patients with HCC, and elevated levels of low expressed circRNAs in patients were associated with MVI negativity in patients with HCC. No publication bias was found. Conclusion PI3K/AKT/mTOR-related circRNAs are potential biomarkers for HCC, especially in the diagnosis of HCC. Due to the small number of included articles and the limitation of the included population, more studies on the diagnostic and prognostic value of PI3K/AKT/mTOR pathway-related circRNAs are needed in the future.

Publisher

Springer Science and Business Media LLC

Reference59 articles.

1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2024

2. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer;Huang DQ;Cell Metab,2022

3. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang JD;Nat Rev Gastroenterol Hepatol,2019

4. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma;Xu RH;Nat Mater,2017

5. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma;J Hepatol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3